Our Pipeline
We have made considerable progress with our branded and generic product development activities. Focusing on our proprietary drug delivery technology expertise and core therapeutic categories, we continue to review strategic additions to our branded and generic product pipelines.
Watson Brands Product Pipeline Status
| Branded Product | Disease/Market | Alliance | Status |
|---|---|---|---|
| TRELSTAR® (triptorelin pamoate for injectable suspension) 6-month formulation | Advanced Prostate Cancer/Urology | Debiopharm | Submitted |
| Novel Oral Contraceptive | Prevention of Pregnancy | Warner Chilcott | Phase 3 |
| URACYST® (sterile sodium chondroitin sulfate) | Interstitial cystitis | Stellar | Phase 2 |
Watson Generics Product Pipeline Status
| Pending ANDA's |
|---|
| ~60 |
